Interview with Richard de Souza, CEO, Martindale Pharma
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
Address: Hubert Road
Brentwood
Essex CM14 4JY
,United Kingdom
Tel: +44 (0) 1277 266 600
Web: http://www.martindalepharma.co.uk/
After starting out as a London chemist store owned by William Martindale, Martindale Pharma has remained in business for more than a century. The company’s reputation as a leading UK manufacturer and supplier of specialty prescription pharmaceutical products for healthcare professionals, working in both Primary and Secondary Care, has grown steadily over that time. Martindale Pharma is now firmly established as a leading supplier to the UK’s NHS and exports its products to a number of other major pharmaceutical markets. Martindale Pharma has a clearly defined mission: to provide medicines to improve the quality of people’s lives.
Martindale Pharma has built strong relationships with prescribers and influencers on drug choice in its chosen business segments (see below). Working on the basis of a partnership, Martindale Pharma has also built a strong relationship with healthcare service providers such as Alliance Boots, Celesio, AAH, Lloyds, Co-Operative Pharmacies, as well as the NHS. Our operating philosophy is one of close co-operation and responsiveness to customer needs.
Key Business Segments:
Addiction
Martindale Pharma is ranked number one in market share in the opiate addiction market, driven by the success of our brand Physeptone, the UK’s leading methadone product. We work in partnership with the NHS, Community Drug Teams, third party providers of addiction services as well as retail pharmacies to ensure that drug service users receive the optimum support as they seek to move away from the use of illicit opiates.
Critical Care
Martindale Pharma manufacture and market the Aurum Range, the UK’s leading range of 11 pre-filled syringes for emergency use by resuscitation and operating theatre teams. We also manufacture and market a Caffeine product for treatment of Apnoea of Prematurity a critical care area in neonatology.
Specials
Martindale Pharma can manufacture over 30,000 products in a range of formulations. Handling around 700-800 individual orders a day for these highly personalised medicines, the majority of products are made by our dedicated team of pharmacists and technical staff. Over 90% of orders are supplied to the customer within 24 hours of ordering. Martindale Pharma is ranked number one by market share in this segment.
Ophthalmics
Martindale Pharma provides a broad range of ophthalmic products as generic, own label and third party brands. We are one of the top three companies in our chosen Ophthalmics disease segments.
Hospital Speciality Products
Martindale Pharma’s range of principally parenteral products are used in a wide range of hospital situations. We are one of the country’s leading manufacturers of sterile injection products supplying over 25 million ampoules a year.
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of the UK’s healthcare system, its expertise in life sciences and…
Christine (Chris) Fox, VP and general manager UK and Ireland at Amgen, two months into her first country manager position and first time in a role outside of North America,…
Geoff Twist, managing director of Roche Diagnostics UK and Ireland, analyses the changing mindset he sees at various levels, leaning towards greater recognition of pathology’s impact on health systems. He…
Jeremy Thorpe established Tillotts Pharma’s operations in the UK, building his team around the central pillar of customer relationships. Jeremy explains how his company’s approach allowed it to reach £25…
Peter Burema, CEO of NextPharma, explains the specificities of a UK-based CDMO with manufacturing sites on the European continent. He describes how NextPharma refocused its efforts on being a customer-centric…
Laura McMullin, General Manager of the pharmaceutical division of Pierre Fabre in the UK and Ireland, explains the huge untapped potential of the organisation and her intention to make the…
With four out of the five NHS bodies, Leeds City Region is strongly anchored in the British life sciences ecosystem. Chair of Leeds City Region Enterprise Partnership, Roger Marsh OBE,…
Thembalath Ramachandran, chairman and managing director of one of the UK’s fastest growing generics manufacturers, Bristol Laboratories, describes why he chose to relocate from India to start his business, the…
Philip Lews Williams, managing director of the UK affiliate of French ophthalmology specialist Théa, describes the evolution of the company’s engagement in the UK and his strategy for taking on…
Having just announced a major investment into a new UK Discovery Centre in London that is set to open in 2020, MSD is committed to leverage on the UK’s potential…
Heading the Life Sciences strategy for Scotland’s main economic development agency Scottish Enterprise, Julia Brown recalls some of the region’s unique features making it an ideal place for life Sciences…
As all eyes are on Takeda these days after its announced acquisition of Shire, Jon Neal, managing director of the UK and Ireland operations of the Japanese player, looks back…
See our Cookie Privacy Policy Here